REG - Hemogenyx Pharma Plc - CDX Development Update

Hemogenyx PharmaceuticalsAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB4537Ca&default-theme=true

RNS Number : 4537C  Hemogenyx Pharmaceuticals PLC  02 September 2024

 

2 September 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

CDX Development Update

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical
group focused on developing treatments for cancers and viral diseases, is
pleased to announce that it has developed a new and improved version of its
bi-specific antibody ("CDX") for the treatment of relapsed/refractory acute
myeloid leukaemia ("AML"), a subset of acute lymphoblastic leukaemia ("ALL"),
and potentially for conditioning in bone marrow transplantations.

 

The Company's scientists utilised Lonza's bYlok
(https://www.lonza.com/biologics/expression-technologies/bYlok) bispecific
pairing technology to develop a new and improved version of CDX, which has
demonstrated significantly enhanced efficacy in in vitro testing. Additional
in vivo studies are currently underway.

 

Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"The development of an improved version of our CDX bi-specific antibody holds
significant promise for enhancing treatment outcomes for patients battling
often incurable blood cancers. This advancement could accelerate the progress
of this product candidate and allow us to resume its development toward the
clinic. It may also attract new industry partners interested in fast-tracking
the co-development of CDX."

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

About AML

AML, the most common type of acute leukemia in adults, has poor survival rates
(a five-year survival rate of less than 30% in adults) and is currently
treated using chemotherapy, rather than the potentially more benign and
effective form of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of the new therapy for AML would have a major impact on
treatment and survival rates for the disease.

About ALL

Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow
that primarily affects children, although it can also occur in adults. Unlike
Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation
of immature lymphocytes, a type of white blood cell. ALL is the most common
childhood cancer, representing approximately 25% of cancer diagnoses in
children. It progresses quickly and requires prompt treatment. While the
overall prognosis for ALL is generally more favorable than AML, certain
subtypes remain challenging to treat. Hemogenyx Pharmaceuticals is developing
innovative treatments specifically targeting a subset of ALL that has proven
particularly difficult to treat, especially in children. The Company's R&D
focuses on addressing the limitations of current therapies and improving
outcomes for patients with these hard-to-treat forms of ALL.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKDBBKBKBDCK